Immunology Behind Tumors: A Mini Review

Author(s): Pooja Hurkat, Sourabh Jain, Richa Jain, Aakanchha Jain*

Journal Name: Current Cancer Therapy Reviews

Volume 15 , Issue 3 , 2019

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: The immune system is designed with great care to distinguish self from non-self, as exhibited by immune responses to different pathogens. Furthermore, the immune system has the capacity to distinguish between self from altered self in case of autoimmune diseases like cancer. Developing tumors bypass the immune system mechanism which restrains selfreactive responses. Immunotherapy is a coherent means since the immune system can eliminate a number of antigens derived from the genetic constitution of B and T lymphocytes. Our understanding of the immune system has developed a great deal.

Conclusion: This review is focused not only on the mechanism by which the immune system protects us but also on the ways in which it can inflict the body and how to modulate it with therapy. Thus, understanding the interaction of a tumor with the immune system provides insights into mechanisms that can be utilized to elicit anti-tumor immune responses. Here, we have recapitulated the function of the tumor microenvironment and immune checkpoints.

Keywords: B cell, T cell, antigen, cancer, immunity, tumor.

[1]
Frankish Helen. 15 million new cancer cases per year by 2020, says WHO. Medicine and Health Policy 361(9365) p1278 2003; Available from:.
[http://dx.doi.org/10.1016/S0140-6736(03)13038-3]
[2]
Restifo NP, Dudley ME, Rosenberg SA. Adaptive immunotherapy for cancer: Harnessing the T cell response. Nat Rev Immunol 2012; 12: 269-81.
[3]
Baxevanis CN, Perez SA. Cancer dormancy: A regulatory role for endogenous immunity in establishing and maintaining the tumor dormant state. Vaccines 2015; 3: 597-619.
[4]
Candéiasa SM, Gaiplb US. The immune system in cancer prevention, development and therapy. Anticancer Agents Med Chem 2016; 16(1): 101-7.
[5]
Begley J, Ribas A. Targeted therapies to improve tumor immunotherapy. Clin Cancer Res 2008; 14(14): 4385-91.
[6]
Dimberu PM, Leonhardt RM. Cancer immunotherapy takes a multi-faceted approach to kick the immune system into gear. Yale J Biol Med 2011; 84(4): 371-80.
[7]
Milo GE, Oldham JW, Zimmerman R, Hatch GG, Weisbrod SA. Characterization of human cells transformed by chemical and physical carcinogens in vitro. In Vitro 1981; 17(8): 719-29.
[8]
Oliveira PA, Colaço A, Chaves R, Guedes-Pinto H, De-La-Cruz PLF, Lopes C. Chemical carcinogenesis. Biomed Med Sci 2007; 79(4): 593-616.
[9]
Daya-Grosjean L. Xeroderma pigmentosum and skin cancer. Adv Exp Med Biol 2008; 637: 19-27.
[10]
Feltcamp MCW, Melief CJM, Cast WM. Peptide specific cytotoxic T lymphocyte directed against viral oncogene products. In: Cancer Clinical Science in Practice Tumor Immunology: Immunotherapy and Cancer Vaccines. Dalgleish AG, Browning MJ. Press Syndicate of University of Cambridge: Cambridge, New York, 1996; pp. 132-9.
[11]
Woller N, Knocke S, Mundt B, et al. Virus-induced tumor inflammation facilitates effective DC cancer immunotherapy in a Treg-dependent manner in mice. J Clin Invest 2011; 121(7): 2570-82.
[12]
Yin YJ, Salah Z, Maoz M, et al. Oncogenic transformation induces tumor angiogenesis: A role for PAR1 activation. FASEB J 2003; 17(2): 163-74.
[13]
Ralph SJ, Rodríguez-Enríquez S, Neuzil J, Saavedra E, Moreno-Sánchez R. The causes of cancer revisited: “Mitochondrial malignancy” and ROS-induced oncogenic transformation – Why mitochondria are targets for cancer therapy. Molecular Aspects of Medicine. Mol Mech New Therapeut Targets Human Carcinogen 2010; 31(2): 145-70.
[14]
Hills SA, Diffley JFX. DNA replication and oncogene-induced replicative stress. Curr Biol 2014; 24(10): R435-44.
[15]
Downward J, Yarden Y, Mayes E, et al. Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature 1984; 307: 521-7.
[16]
Surmacz E. Growth factor receptors as therapeutic targets: Strategies to inhibit the insulin-like growth factor I receptor. Oncogene 2003; 22: 6589-97.
[17]
Cantley LC, Auger KR, Carpenter C, et al. Oncogenes and signal transduction. Cell1 991 64(2): 281-302.
[18]
Introna M, Golay J. How can oncogenic transcription factors cause cancer: A critical review of the myb story. Leukemia 1999; 13(9): 1301-6.
[19]
Lodish H, Berk A, Zipursky SL, et al. Molecular Cell Biology. In: Proto-Oncogenes and Tumor-Suppressor Genes. 4th ed. Freeman WH and Company New York 2000.
[20]
Osborne BA, Lawrence M, Schwartz LM. Essential genes that regulate apoptosis. Trends Cell Biol 1994; 4(11): 394-9.
[21]
Cory S. Activation of cellular oncogenes in hemopoietic cells by chromosome translocation. Adv Cancer Res 1986; 47: 189-234.
[22]
Cho KR, Hedrick L. Genetic alterations in human tumors. Genet Instab Tumorigen 1997; 21: 149-76.
[23]
Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature 2009; 461: 1071-8.
[24]
Zagurya D, Buaneca HL, Bizzinia B, Burnyb A, Lewisc G, Galloc RC. Active versus passive anti-cytokine antibody therapy against cytokine-associated chronic diseases. Cytokine Growth Factor Rev 2003; 14(2): 123-37.
[25]
Albertson DG. Gene amplification in cancer. Trends Genet 2006; 22(8): 447-55.
[26]
Schwab M. Amplification of oncogenes in human cancer cells. BioEssays 1998; 20(6): 473-9.
[27]
Santarius T, Shipley J, Brewer D, Stratton MR, Cooper CS. A census of amplified and overexpressed human cancer genes. Nat Rev Cancer 2010; 10: 59-64.
[28]
Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity 2013; 39(1): 1-10.
[29]
Finn OJ. Cancer immunology. N Engl J Med 2008; 358: 2704-15.
[30]
Melvold RW, Sticca RP. Basic and tumor immunology: A review. Surg Oncol Clin N Am 2007; 16(4): 711-35.
[31]
Zarour HM, Ferrone S. Cancer immunotherapy: Progress and challenges in the clinical setting. Eur J Immunol 2011; 41(6): 1510-5.
[32]
Vigneron N, Stroobant V, Van den Eynde BJ, van der Bruggen P. Database of T cell-defined human tumor antigens: The 2013 update. Cancer Immun 2013; 15(13): 15.
[33]
Coulie PG, Van den Eynde BJ, van der Bruggen P, Boon T. Tumour antigens recognized by T lymphocytes: At the core of cancer immunotherapy. Nat Rev Cancer 2014; 14(2): 135-46.
[34]
Disis ML, Cheever MA. Oncogenic proteins as tumor antigens. Oncogenic proteins as tumor antigens. Curr Opin Immunol 1996; 8(5): 637-42.
[35]
Maher J, Davies ET. Targeting cytotoxic T lymphocytes for cancer immunotherapy. Br J Cancer 2004; 91(5): 817-21.
[36]
Wu J, Lanier LL. Natural killer cells and cancer. Adv Cancer Res 2003; 90: 127-56.
[37]
Lamagna C, Aurrand-Lions M, Imhof BA. Dual role of macrophages in tumor growth and angiogenesis. J Leukoc Biol 2006; 80(4): 705-13.
[38]
Attarwala H. Role of antibodies in cancer targeting. J Nat Sci Biol Med 2010; 1(1): 53-6.
[39]
Dunn GP, Old LJ, and Schreiber RD. The three ES of cancer immunoediting. Annu Rev Immunol 2004; 22: 329-60.
[40]
Igney FH, Krammer PH. Immune escape of tumors: Apoptosis resistance and tumor counterattack. J Leukoc Biol 2002; 71(6): 907-20.
[41]
Bubeník J. MHC class I down-regulation: tumour escape from immune surveillance? Int J Oncol 2004; 25(2): 487-91.
[42]
Munn DH, Mellor AL. The tumor-draining lymph node as an immune-privileged site. Immunol Rev 2006; 213: 146-58.
[43]
Uekusa Y, Gao P, Yamaguchi N, et al. A role for endogenous IL-12 in tumor immunity: IL-12 is required for the acquisition of tumor-migratory capacity by T cells and the development of T cell-accepting capacity in tumor masses. J Leukoc Biol 2002; 72(5): 864-73.
[44]
Nakajima C, Uekusa Y, Iwasaki M, et al. A role of interferon-gamma (IFN-gamma) in tumor immunity: T cells with the capacity to reject tumor cells are generated but fail to migrate to tumor sites in IFN-gamma-deficient mice. Cancer Res 2001; 61(8): 3399-405.
[45]
Bieging KT, Mello SS, Attardi LD. Unravelling mechanisms of p53-mediated tumour suppression. Nat Rev Cancer 2014; 14: 359-70.
[46]
Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 2007; 25: 267-96.
[47]
Gattinoni L, Powell DJ Jr, Rosenberg SA, Restifo NP. Adoptive immunotherapy for cancer: Building on success. Nat Rev Immunol 2006; 6: 383-93.
[48]
Rosenberg SO. Animal models of tumor immunity, immunotherapy and cancer vaccines. Curr Opin Immunol 2004; 16(2): 143-50.
[49]
Leavy O. Immunotherapy: A triple blow for cancer. Nat Rev Cancer 2015; 15: 258-9.
[50]
Cui TX, Kryczek I, Zhao L, et al. Myeloid-derived suppressor cells enhance stemness of cancer cells by inducing microRNA101 and suppressing the corepressor CtBP2. Immunity 2013; 39(3): 611-21.
[51]
Zhao E, Maj T, Kryczek I, et al. Cancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction. Nat Immunol 2016; 17(1): 95-103.
[52]
Wieder T, Eigentler T, Brenner E, Röcken M. Immune checkpoint blockade therapy. J Allergy Clin Immunol 2018; 142(5): 1403-14.
[53]
Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science 2018; 359(6382): 1350-5.
[54]
Gubin MM, Zhang X, Schuster H, et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 2014; 515(7528): 577.
[55]
Korman AJ, Peggs KS, Allison JP. Checkpoint blockade in cancer immunotherapy. Adv Immunol 2006; 90: 297-339.
[56]
Webb ES, Liu P, Baleeiro R, Lemoine NR, Yuan M, Wang YH. Immune checkpoint inhibitors in cancer therapy. J Biomed Res 2018; 32(5): 317-26.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 15
ISSUE: 3
Year: 2019
Page: [174 - 183]
Pages: 10
DOI: 10.2174/1573394714666180907143433
Price: $65

Article Metrics

PDF: 28
HTML: 2
EPUB: 1
PRC: 1